On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
The 2018 Nobel Prize announcement recognized the discovery of the “entirely new principle for cancer therapy” of negative immune regulation. It also cited the pharmaceutical industry’s lack of interest. Ultimately, a small biotech company developed both the anti-CTLA-4 antibody Yervoy/ipilimumab, based on James Allison’s work, and the anti-PD-1 antibody Opdivo/nivolumab based on Tasuku Honjo’s work. This talk will discuss why pharmaceutical companies were not interested, why these products were developed by the biotech company Medarex, and how this example highlights the results of new research into the origins of the most innovative medicines of the past two decades.
